Abstract
One hundred and twelve patients received hematopoietic stem cell transplantation (HSCT), including 91 patients with acute leukemia, 12 patients with chronic myeloid leukemia, 7 patients with lymphoma and 2 patients with myeloma and neuroblastoma respectively. Among them, 14 patients were treated with unpurged autologous bone marrow transplantation (ABMT), 25 patients with purged autologous bone marrow transplantation (PABMT), 40 patients with autologous peripheral blood hematopoietic stem cell transplantation (APBHSCT), 24 patients with allogeneic bone marrow transplantation (Allo-BMT), 9 patients with fetal liver hematopoietic stem cell transplantation (FLHSCT). The three year disease free survival (DFS) rates in these five groups were 683%, 67.5%, 69.54%, 57.12% and 3333% respectively. The relapse rates were 30.76%, 26.80%, 20.8%, 13% and 62.5% respectively. In contrast, in the conventional chemotherapy group, the three year DFS rate and relapse rate were 738% and 76.4% respectively. These results indicated that the APBHSCT group had a quicker hematopoietic reconstitution with less complication of infection. All of these five transplantation groups had much higher three years disease free survival rates than that of the conventional chemotherapy group.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
